The overall objective of the SysMedPD project is to further explore and identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson’s Disease (PD) patients with overt mitochondrial dysfunction.
The Coordinating Action Systems Medicine (CASyM) in collaboration with the Federation of European Biochemical Societies (FEBS) organized the first European Summer School in Systems Medicine: Implementation of Systems Medicine across Europe.
U-BIOPRED (“Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes”) was a 5-year European-wide IMI-funded project (IMI-115010) which aimed to understand more about severe asthma, determine how it differs from person to person, and uncover new information and ideas that could lead to the creation of effective new treatments.
The overarching aim of the Open Multiscale Systems Medicine (OpenMultiMed) COST Action is to gather a critical mass of international researchers and coordinate them as a team that develops and evaluates a transdisciplinary framework for multiscale systems medicine, consisting of novel concepts, methodologies and technologies.
“Avicenna – A Strategy for in silico Clinical Trials” was a Coordination and Support Action funded by the European Commission. Avicenna was tasked with writing a Roadmap to define the strategy for developing In Silico Clinical Trials.
The main goal of the CombiMS project is to identify a new method for drug discovery based on systems biology and to validate this approach by identifying novel combination therapies for Multiple Sclerosis.
The main goal of the PRIAT Project consists in the development and use of HLA peptidome analysis for the study of interpatient and intrapatient variations in the immunopeptidome in response to antibody treatment.